Bimekizumab provides rapid and sustained improvements in quality of life that correlate with clinical outcomes in patients with moderate to severe plaque psoriasis: 60 week results from a randomized , double blinded , Phase 2b extension study

Main Article Content

Kim A Papp
Probity Medical Research and K Papp Clinical Research, Waterloo, ON, Canada

Joseph F Merola
Harvard Medical School, Brigham and Women's Hospital, Boston, MA, USA

Alice B Gottlieb
Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY, USA

Christopher EM Griffiths
Dermatology Centre, University of Manchester, Manchester, UK

Kristina K Harris
UCB Pharma, Hong Kong, China

Nancy Cross
UCB Pharma, Raleigh, NC, USA

Luke Peterson
UCB Pharma, Raleigh, NC, USA

Christopher Cioffi
UCB Pharma, Brussels, Belgium

Andrew Blauvelt
Oregon Medical Research Center, Portland, OR, USA

Keywords

psoriasis, bimekizumab

Abstract

Abstract not available.

References

1. Glatt S et al. Br J Clin Pharmacol. 2017;83:991-1001.

2. Papp KA et al. J Am Acad Dermatol. 2018:79:279-286.

3. Papp KA et al. EADV. 2018 [e poster P1978].

4. Blauvelt A et al. AAD. 2019 (oral presentation OP11180).

5. Armstrong AW et al. PLoS One. 2012;7(12):e52935.

6. Strober B et al. BMJ Open. 2019;9(4): e027535.

7. Griffiths CEM et al. Br J Dermatol. 2018;179:173-181.

8. Korman NJ et al. Dermatol Online J. 2015;21(10):pii: 13030/qt1x16v3dg

9. Augustin M et al. Br J Dermatol 2018;179:1385-1391.

Article Sidebar

Poster PDF
Published
Nov 9, 2019
DOI https://doi.org/10.25251/skin.3.supp.35

Article Details

How to Cite
Papp, K. A., Merola, J. F., Gottlieb, A. B., Griffiths, C. E., Harris, K. K., Cross, N., Peterson, L., Cioffi, C., & Blauvelt, A. (2019). Bimekizumab provides rapid and sustained improvements in quality of life that correlate with clinical outcomes in patients with moderate to severe plaque psoriasis: 60 week results from a randomized , double blinded , Phase 2b extension study. SKIN The Journal of Cutaneous Medicine, 3, S35. https://doi.org/10.25251/skin.3.supp.35
Issue
Vol. 3 (2019): Supplemental Issue: Scientific Posters Presented at 2019 Fall Clinical Dermatology Conference®-Las Vegas
Section
Poster Presentations from FC23 Dermatology Conference®: Psoriasis
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose. Permitted reuse is defined by  the following user license:
 

Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation. 

Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.ca/ojs/.

Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.

Most read articles by the same author(s)

<< < 4 5 6 7 8 9 10 > >>